Clinical trials
Positron Emission Tomography clinical trials
Below are recruiting positron emission tomography clinical trials, each written for real people, not researchers. We’re tracking 344 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Fort Smith, ArkansasAges 18 years+ - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Goodyear, ArizonaAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Birmingham, AlabamaAges 18 years+ - NCT06914999RecruitingEarly Phase 1
Comparing a new scan to standard scan during head and neck cancer radiation
This trial is testing whether a newer type of PET/CT scan (F-18 NaF) can better detect blood vessel problems caused by radiation therapy than the standard scan (F-18 FDG) in people with head and neck cancer. If successful, it could lead to better ways to prevent and manage these complications.
Atlanta, GeorgiaAges 18 years+ - NCT06067269RecruitingPhase 2
Hormone therapy and precise radiation for intermediate-risk prostate cancer
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Los Angeles, CaliforniaAges 18 years+ - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Birmingham, AlabamaAges 18 years+ - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
New Haven, ConnecticutAges 18–80 - NCT07225985RecruitingPhase 1/Phase 2
Pralatrexate, bendamustine, and radiation before donor stem cell transplant for T-cell lymphoma
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
Seattle, WashingtonAges 18 years+ - NCT06647953RecruitingPhase 3
Testing a standard approach for pleuropulmonary blastoma, with or without topotecan
This trial compares a standard surgery and chemotherapy plan for type I pleuropulmonary blastoma (PPB) to adding the drug topotecan for types II and III PPB. The goal is to see if the extra drug helps shrink tumors and improve outcomes for children with more advanced disease.
Birmingham, AlabamaAges Up to 21 years - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT06386315RecruitingPhase 2
Lower dose radiation for slow-growing lymphoma
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
Scottsdale, ArizonaAges 18 years+ - NCT06389786Recruiting
Using a new PET scan to find cancer spread before prostate surgery
This trial tests a special PET/MRI scan that may help doctors see if prostate cancer has spread to nearby lymph nodes before surgery. It could help guide treatment decisions for men with high-risk prostate cancer.
Jacksonville, FloridaAges 30–85 - NCT06064097RecruitingPhase 2
Nivolumab plus chemo for young people with nasopharyngeal cancer
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Birmingham, AlabamaAges Up to 21 years - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT03716401Recruiting
Imaging tests to predict kidney disease in type 2 diabetes
This study uses special kidney imaging to look for patterns that can predict how diabetic kidney disease may progress. It may help researchers find better ways to identify people at higher risk using noninvasive (and possibly biopsy-related) tests.
TurkuAges 18–80 - NCT04416165Recruiting
FDG versus FAPI PET scans for different cancers
This study compares two types of PET/CT scans—one that uses FDG and one that uses FAPI—to help doctors see and evaluate cancer in different situations. It may help improve how well scans detect tumors and guide care, though it requires getting both scans scheduled.
Xiamen, FujianAges 18–90 - NCT04235114RecruitingPhase 1/Phase 2
PET scan test for EGFR-positive cancers using an antibody tracer
This study tests a special PET scan agent (an antibody tracer) to help doctors see EGFR-positive cancers without needing invasive procedures. It is mainly for early testing (Phase 1/2) to understand how well it works for imaging.
Saskatoon, SaskatchewanAges 18–80 - NCT07809438RecruitingPhase 2
Comparing PET scans for early Parkinson's detection
This study tests two different PET scan resolutions to see which is better at detecting signs of early Parkinson's. It is for people who are already part of a Parkinson's research study and may help improve early diagnosis.
New Haven, ConnecticutAges 18 years+ - NCT05610098Recruiting
Study of gene activity in spinal tuberculosis
This trial looks at patterns of gene activity (from blood/tissue samples) in adults with spinal tuberculosis. The goal is to better understand the disease and how to tell different conditions apart, which may help future care.
Cape Town, Western CapeAges 18 years+ - NCT05996432RecruitingEarly Phase 1
Using imaging to guide radiation therapy for head and neck cancer or brain tumors
This trial uses a special PET scan tracer called 18F-FMISO to see areas of low oxygen (hypoxia) in your tumor. The results may help doctors adjust your radiation plan to target those areas more precisely.
Nashville, TennesseeAges 18 years+ - NCT07655518RecruitingPhase 1
PET scan study of BMS-986521 in healthy adults
This study tests a new drug called BMS-986521 using a special brain scan (PET scan) to see how well it attaches to certain receptors in the brain. It is for healthy volunteers to help understand how the drug works.
LeuvenAges 18–55 - NCT07618936Recruiting
PD-L1 PET/CT imaging scan for cancer patients
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
Hefei, AnhuiAges 18–80 - NCT07617688RecruitingEarly Phase 1
PET imaging tracer safety study in healthy volunteers
This early-stage study tests a new PET imaging agent (a radioactive tracer used in medical imaging) to understand how it moves through the body and the radiation dose it delivers. Researchers need healthy volunteers to help establish whether this imaging tool is safe for future patient use.
New Haven, ConnecticutAges 18–60 - NCT07593976RecruitingPhase 2
New PET scan to predict breast cancer treatment response
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
RouenAges 18 years+
Hear when a new Positron Emission Tomography trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for positron emission tomography?
- Yes. Clin2 currently lists 344 recruiting positron emission tomography studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a positron emission tomography trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a positron emission tomography trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.